Logo

Sadashi Suzuki and Wendell Wierenga

Sep 06, 2002
Premium

Sadashi Suzuki has been hired as Affymetrix’ s general manager for Japan and will work out of the new Affymetrix Japan Tokyo office, which will open in January. Suzuki has 25 years experience in the pharmaceutical, healthcare, and life sciences industries at companies such as Kyowa Hakko Kogyo, Baxter International, and Alcon Laboratories.

Wendell Wierenga, CEO of Syrrx, has joined Ciphergen Biosystems’ board of directors. Wierenga joined Syrrx as CEO in September 2000, after working for Pfizer and Warner-Lambert.

Filed under

Microarrays & Multiplexing
microarrays
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.